Tango Therapeutics (NASDAQ:TNGX) Shares Up 7.1% - What's Next?

Key Points

• Tango Therapeutics shares saw a significant increase of 7.1% during recent trading, reaching a last price of $6.47, which is considerably above its previous close of $6.04.
• Analysts remain optimistic, with a consensus rating of "Buy" and an average target price of $10.50, despite the company reporting a loss of ($0.36) EPS for the last quarter.
• Institutional investors own approximately 78.99% of Tango Therapeutics, indicating strong institutional interest as several funds have recently increased their holdings in the company.

Tango Therapeutics, Inc. (NASDAQ:TNGX - Get Free Report) shares traded up 7.1% during mid-day trading on Friday . The stock traded as high as $6.42 and last traded at $6.47. 1,601,358 shares changed hands during trading, a decline of 8% from the average session volume of 1,742,398 shares. The stock had previously closed at $6.04.

Analyst Ratings Changes

Separately, HC Wainwright reissued a "buy" rating and set a $13.00 price target on shares of Tango Therapeutics in a report on Monday, April 14th. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, Tango Therapeutics currently has an average rating of "Buy" and an average price target of $10.50.

Tango Therapeutics Price Performance

The firm has a market cap of $707.79 million, a price-to-earnings ratio of -5.35 and a beta of 1.63. The firm's fifty day moving average is $5.10 and its two-hundred day moving average is $3.05.

Tango Therapeutics (NASDAQ:TNGX - Get Free Report) last posted its quarterly earnings data on Monday, May 12th. The company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.02). The company had revenue of $5.39 million during the quarter, compared to analyst estimates of $6.73 million. Tango Therapeutics had a negative return on equity of 62.75% and a negative net margin of 322.67%. On average, equities analysts forecast that Tango Therapeutics, Inc. will post -1.19 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Tango Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the business. TCG Crossover Management LLC acquired a new stake in Tango Therapeutics in the 4th quarter valued at about $33,174,000. Boxer Capital Management LLC acquired a new stake in Tango Therapeutics in the 4th quarter valued at about $32,077,000. Gilead Sciences Inc. acquired a new stake in Tango Therapeutics in the 4th quarter valued at about $15,000,000. Farallon Capital Management LLC acquired a new stake in Tango Therapeutics in the 4th quarter valued at about $12,360,000. Finally, Balyasny Asset Management L.P. lifted its holdings in Tango Therapeutics by 22.0% in the 4th quarter. Balyasny Asset Management L.P. now owns 3,279,196 shares of the company's stock valued at $10,133,000 after acquiring an additional 592,000 shares during the last quarter. 78.99% of the stock is owned by institutional investors and hedge funds.

Tango Therapeutics Company Profile

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.